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Abstract
AIM: Only a minority of patients carrying a defined viral
aetiologic agent develop cirrhosis and ultimately
hepatocellular carcinoma (HCC), the mechanism underlying
the worsening is still undefined. Experimental infection by
Helicobacter hepaticus in mice causes chronic hepatitis and
HCC and recently, more Helicobacter species (Helicobacter
spp.) have been detected in the liver of patients suffering
from cholestatic diseases and HCC arising from non-cirrhotic
liver. We investigated whether Helicobacter spp. sequences
could be detected in the liver of patients with cirrhosis and
HCC compared to subjects with metastasis to liver from
colon cancer.
METHODS: Twenty-three liver samples from patients
operated upon for HCC superimposed on hepatitis C virus
(HCV)-related cirrhosis and 6 from patients with resected
metastases from colorectal cancer, were tested by polymerase
chain reaction for presence of genomic 16S rRNA of
Helicobacter genus using specific primers. DNA sequencing
and cag A gene analysis were also performed.
RESULTS: Genomic sequences of Helicobacter spp. were
found in 17 of 20 (85%) liver samples from patients with
HCC and in 2 of 6 samples from patients with liver metastasis.
In three samples of the first group the result was uncertain.
H pylori was revealed in 16 out of 17 positive samples and
Helicobacter pullorum in the other.
CONCLUSION: Helicobacter spp., carcinogenic in mice,
were found at a higher frequency in the liver of patients
with HCV-related cirrhosis and HCC than those in patients
without primary liver disease.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fourth cause of cancer
death worldwide[1]. This tumor often follows chronic liver
inflammation and longstanding cirrhosis. Cirrhosis of the liver
is a diffuse process, characterised by fibrosis and nodule
formation, which stems from hepatocellular injury. The cellular
necrosis might originate from viral, toxic, metabolic and
autoimmune sources[2]. Moreover, hepatitis B and hepatitis C
viruses (HBV and HCV) are well-known etiologic factors for
liver cirrhosis, and have been classified by the International
Agency for Research on Cancer (IARC) as type I liver
carcinogens. Both viruses are highly prevalent in the adult
population in Italy[3,4]. Both viral and host characteristics have
been reported to influence the outcome of HBV or HCV
infection and the development of cirrhosis, but they do not
explain all the epidemiological variations of the disease. For
instance, in the case of HCV, the viral genotype 1b[5] has been
repeatedly connected with severity of liver outcome, although
in other reports this issue has been debated[6]. Host characteristics
also play an important role in the pathogenesis of liver disease.
For example, HLA class II haplotype DR5 has been shown to
protect patients from the development of cirrhosis[7].
     Chronic inflammation per se is known to be a factor of
progression towards cancer[8], though HCV in itself does not
appear to foster a strong inflammatory mechanism[9]. It is thus
not yet clear what factors most influence the outcome of the
liver disease. Searching for other noxae has therefore become
mandatory. A new infectious agent, Helicobacter hepaticus
(H. hepaticus), that causes chronic active hepatitis and
associated liver tumors in A/J Cr mice, has been described
by Ward et al[10]. Recently, other Helicobacter species
(Helicobacter spp.), including Helicobacter pylori (H pylori),
bacteria associated with the pathogenesis of gastric[11-14] and
extradigestive manifestations[15,16], have been detected in the
liver of persons suffering from cholestatic diseases and HCC
arising from non-cirrhotic liver[17,18]. We have previously
reported a high frequency of H pylori and Helicobacter
pullorum (H.pullorum) sequences detected by the polymerase
chain reaction (PCR), in the liver of patients with cirrhosis
and superimposed HCC[19].
      To demonstrate a role of the bacteria as a co-factor in the
development of end-stage of liver disease in humans, it is
fundamental to evidence whether Helicobacter occurs at the
same frequency in the liver of patients without primary liver
disease. The present study investigated whether Helicobacter
spp. genomes could be detected in liver specimens from patients
without any diagnosis of chronic active hepatitis, cirrhosis or
HCC, compared with specimens from HCC patients. Therefore,
we analysed liver samples from subjects operated upon for
metastasis to the liver from colon cancer and, the presence of
Helicobacter was assayed by molecular methods.
MATERIALS AND METHODS
Liver samples were obtained during the surgical excision for
cure from 23 patients operated upon for HCC superimposed
on hepatitis C virus (HCV)-related cirrhosis and from 6 patients
suffering from metastatic cancer to the liver, in whom surgery
might obtain remission of the disease. All samples were
immediately frozen in liquid nitrogen and stored at -80  prior
to testing. The architectural pattern and histologic grade of
tumor differentiation of HCC were recorded in accordance
with World Health Organisation (WHO) proposals[20]. HCV
infection was demonstrated by means of an ELISA (Axsym
System, Abbott Diagnostics) and an RIBA (RIBA II, LIA,
HCV3, Sorin, Saluggia, Italy), and confirmed through detection
of circulating HCV-RNA in a PCR.
DNA extraction from liver tissues
Approximately 3 mm3 of tissue was cut and incubated with
0.4 mg/ml proteinase K (Sigma, St Louis) in 0.5 ml extraction
buffer (10 mM Tris- HCl, pH 7.5; 1 mM ethylene diamine
tetra acetate or EDTA, pH 8; 0.25M  sodium chloride; 0.2%
sodium dodecyl sulphate or SDS) at 56  on an agitator until
total tissue digestion, the proteinase K was inactivated by
boiling it for 10 min. The mixture was centrifuged at 14 000
rpm (Eppendorf centrifuge 5415 C) at room temperature, and
to the supernatant, 1 volume of phenol/chloroform (1:1 ratio,
equilibrated with 0.1 M phosphate buffered saline, pH 7.5)
was added. After vortexed and centrifuged at 14 000 rpm, the
aqueous phase was precipitated with 2 volumes of 100%
ethanol containing 10% volume of 3M sodium acetate, pH 4.8
at -80  for 20 min or at -20  overnight. After two washes
with 75% ethanol, the pellet was dried and resuspended in
300 ml TE buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH
8) for further use.
Nested-PCR
Amplification of 16S rRNA gene  Samples were amplified
by Helicobacter genus-specific 16S ribosomal RNA(16S
rRNA) primers (designated Heli, Table 1) that could identify
genomic sequences of 26 species of Helicobacter.
First amplification step  Genomic DNA was amplified in a
total volume of 50 ml containing PCR buffer (1X), 200 µM
dNTP, 4 mM Mg 2+, 0.2 mM primers (Heli-nest-S and Heli-
nest-R, Table 1), 1 U Taq DNA polymerase (GibcoBRL, USA)
and 1 mg of total DNA. The reaction mixture was initially
denatured for 2 min at 94  then amplified for 35 cycles as
follows: denaturation for 30 s at 94 , primer annealing for
30 s at 55  and extension for 1.5 min at 72 . A final
extension step was done for 5 min at 72  (Thermocycler
HYBAID–OmniGene TR3 5M2-UK). An amplification product
of 1 300 bp by the forward and reverse primers was expected.
Second amplification step  PCR was repeated as above with
minor alterations: 1 ml of amplicon was used from the first
amplification step, the annealing temperature was brought to
60 , extension time lasted 30 s for 35 cycles and Heli-R/
Heli-S primers (Table 1) were used. The expected size of the
amplicon was 480 bp.
Amplification of cag A gene
Samples generating a positive result from the Nested-PCR were
subsequently analysed with a different pair of primers (CagA,
Table 1). The CagA-1 and CagA-2 primers used  (Table 1)
amplified a 290 bp product from the 128 KDa Cag A protein,
typical of H pylori[21]. Fifty microliter of reaction mixture was
prepared containing PCR buffer (1X), 2 mM of Mg 2+, 200 mM
dNTP, 0.2 mM primers, 1 U of Taq DNA polymerase and 1 mg
of DNA. Amplification consisted of an initial denaturation
for 2 min at 94  then amplified for 50 cycles as follows:
for 30 s at 94 , for 30 s at 61  and for 1 min at 72 .
Extension was continued for another cycle for 5 min at 72 .
The PCR products were analysed on a 2% agarose gel. Positive
and negative controls were included. VCS Hae III and VCS
Hinf I were used as DNA size standard for amplification with
Heli primers and Cag A primers, respectively.
Table 1  Primers used for amplification of 16S rRNA and cag
A genes
Primers         Sequences 5’ 3’
Heli-nest.S         5’ att agt ggc gca cgg gtg agt aa 3’
Heli-nest-R         5’ ttt agc atc ccg act taa ggc 3’
Heli-S         5’ gaa cct tac cta ggc ttg aca ttg 3’
Heli-R         5’ ggt gag tac aag acc cgg gaa  3’
CagA-1         5’ ata atg cta aat tag aca act tga gcg a 3’
CagA-2         5’tta gaa taa tca aca aac atc acg cca t 3’
Southern blot hybridisation
For this purpose, 10 ml of the amplified DNA samples was
electrophoresed on a 1% agarose gel. The samples were then
transferred to nylon hybond N+ membrane (Amersham
Pharmacia Biotech Inc., UK) treated with denaturing agent
(0.5 M sodium hydroxide, 1.5 M sodium chloride). The
membrane was then neutralised with 5X SSC (0.75M sodium
chloride and 0.075M sodium acetate) for 1 min. The membrane
was prehybridised in buffer (5X SSPE (0.6 M NaCl, 40 mM
NaH2PO4, 4 mM EDTA), 0.5% SDS, 5X Denhardt’s solution,
0.02 mg/ml Salmon sperm) at 65  for 4 h. A freshly
denatured probe, amplified from H. pullorum DNA and
labelled with P 32(RediprimeTM II, random labelling system,
Amersham Pharmacia Biotech Inc., UK) according to the
manufacturer’s instructions, was purified using MicrospinTM
S-400 (HR Columns, Amersham Pharmacia Biotech Inc., New
Jersey, USA). Hybridisation was performed overnight at 65
in hybridisation solution containing blocking reagent (5X
SSPE, 0.5% SDS, 5X Denhardt’s solution) and the DNA probe.
The nylon membrane was then washed in 2X SSC, 0.1% SDS
for 15 min at RT, 2X SSC, 0.1% SDS for 15 min at 65 , 1X
SSC, 0.1% SDS for 15 min at 65  and 0.5X SSC, 0.1% SDS
for 10 min at 65 . The bound probes were finally detected by
autoradiography after 4 h at RT (Kodak scientific imaging film,
X-OMAT/AR, Rochester, New York).
Sequencing of DNA
PCR-amplified Helicobacter genus-specific PCR products
were run on a 2% agarose gel, purified using the QIAquick
gel extraction kit (QIAGEN, Germany) and sequence analysis
was performed with an Applied Biosystems DNA sequencer
(Perkin-Elmer, Applied Biosystems, Warrington, Great Britain)
following the procedure of the manufacturer, using the ABI
PRISM 310 big dye terminator cycle sequencing kit. The
sequences were entered, aligned and compared with known
Helicobacter species using the BLAST programme (Genetics
Computer Group, Madison, Wis.).
RESULTS
Screening for Helicobacter genus
We found DNA sequences typical of Helicobacter spp. in 17
of 20 (85%) livers from patients operated for HCC using
Helicobacter genus-specific 16S rRNA primers. Three samples
(15%) were negative, while in the remaining 3 out of 23, the
results were uncertain. Two of 6 liver samples obtained from
6 patients whose livers were resected for metastasis due to
colon cancer, contained sequences typical of Helicobacter spp.
      The 480 bp product obtained in the second round of the
nested-PCR with Heli primers is shown in Figure 1. The liver
samples with a positive result by this method were all positive
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by Southern blot hybridisation using P 32-labelled probe
generated from H.pullorum DNA (data not shown). These results
confirmed the presence of Helicobacter gene sequences in the
liver samples analysed from patients with cirrhosis and HCC.
Figure 1  Agarose gel (2%) showing PCR products obtained
with Helicobacter genus-specific 16S ribosomal RNA primers.
Lane 1 negative control (DEPC-treated water). Lanes 3 and 4
liver samples from patients with metastatic liver cancer. Lanes
2, 5, 6, 7, 8 and 9 positive liver samples. Lane 10 positive con-
trol (H. hepaticus DNA). MW molecular-weight marker (VCS
Hae III).
Type I H pylori identification
The patients whose liver samples gave a signal typical for
Helicobacter genus with Heli primers (Table 1), were analysed
with primers specific for the amplification of a 290 bp stretch
of the cag A gene[21]. The bands amplified corresponded to the
expected size (Figure 2).
      Overall, 16 out of 17 (94%) liver tissues from patients who
were positive when tested for Helicobacter genus, were also
found to be positive when tested for the presence of a sequence
that was typical only for type I Helicobacter pylori, i.e., the
cag A gene.
Figure 2  Analysis of cagA-specific PCR products from
Helicobacter genus positive liver samples of patients with cir-
rhosis and HCC. The 290 bp fragments were examined on 2%
agarose gel electrophoresis. Lane 1 negative control (DEPC-
treated water). Lanes 2 to 6 Helicobacter genus positive liver
samples. Lanes 7 and 8 positive controls (cagA-cDNA). MW
molecular-weight marker (VCS Hinf I). Lanes 2, 3, 5, and 6
positive for amplified cagA fragment. Lane 4 negative for cagA.
Presence of H pylori confirmed after DNA sequencing
The Helicobacter positive DNA fragments were sequenced.
Comparison of DNA sequences of the genomic 16S rRNA
amplicons with those of known Helicobacter spp. was
performed using sequence alignment with the BLAST
programme. The presence of H pylori and H. pullorum
sequences was thus confirmed in these liver samples.
DISCUSSION
Despite the profound impact of HCC on human health
worldwide[22], its pathogenesis remains uncertain. Thanks to
the availability of very efficient vaccines that could prevent
HBV infection, WHO has sought to eradicate HBV infection
and hence its long-term consequences such as HCC. However,
in most industrialised countries, it has been shown that neither
HBV nor Schistosoma infections play a major role in the
development of HCC, instead, the majority of patients carry
HCV. This virus does not integrate into host DNA, and it is
likely that the mechanism of carcinogenesis differs from that
of HBV. Therefore, the need to clarify the pathogenic
mechanisms by which HCV may lead to liver cancer has
become of prime importance.
     Since the currently known risk factors cannot explain all
aspects of its progression to HCC, other causal mechanisms
should be explored[23]. From an epidemiological aspect, several
studies have evidenced a high seroprevalence of H pylori
among cirrhotic subjects[24-26], but these data have not been
ubiquitarily confirmed[27]. Part of these differences might be
explained by geographical and clinical differences in the
population studied and the study-design[23]. Experimentally,
Ward et al. have fulfilled Koch’s postulates as far as the
association of H. hepaticus with chronic active hepatitis and
HCC in mice was concerned[10]. Whether Helicobacter spp.
could act as a cofactor in the progression towards cirrhosis
and carcinogenesis in humans with viral hepatitis, is still under
review[23].
     Chronic hepatitis is an inflammatory disease and each
inflammatory process is characterised by increased levels of
pro-inflammatory cytokines such as interleukins 1, 6 (IL-1,
IL- 6), tumor necrosis factor (TNF) and by the presence of
lympho-mono cellular infiltrate and lymphoid follicle
formation[28]. Viruses, such as HCV, are only capable of limited
inflammation, due to shedding IL-1 receptor in circulation,
thereby limiting the possibility of IL-1 binding to cellular
receptors[23]. Helicobacters, on the other hand, are strong
inducers of the inflammatory cascade[29], infection with them
could lead to the accumulation of extraordinary number of
lymphocytes and polymorphonuclear cells in the infected
tissue. IL-1 gene cluster polymorphisms, thought to enhance
IL-1b production, confer an increased risk of cancer in patients
infected with H pylori[30]. Furthermore, Meyer-ter-Vehn et al
have recently shown that strains of Cag-A-expressing H pylori
could activate the ERK/MAP kinase cascade, resulting in
Elk-1 phosphorylation and increased c-fos transcription. Proto-
oncogene activation might represent a crucial step in the
pathomechanism of H pylori-induced neoplasia. It has been
shown that several Helicobacter spp. could also secrete a liver-
specific toxin that causes hepatocyte necrosis in cell culture,
and might therefore also be involved in damaging liver
parenchyma in vivo.
      The possibility that Helicobacter spp. could infect the biliary
tract and the liver of humans has been reported by several
studies in different settings. Fox et al have shown the presence
of Helicobacter spp. in the bile of Chileans with chronic
cholecystitis. Avenaud and coworkers have demonstrated by
PCR the presence of genomic sequences of Helicobacter spp.
in the liver of 8 patients with HCC without primary diagnosis
of cirrhosis, a further analysis by sequencing revealed that these
species were H pylori and Helicobacter felis[18]. Similarly, we
have reported the presence of the cagA gene sequences
obtained from the liver tissue of cirrhotic patients with HCC
[19]. Furthermore, Nilsson et al have identified H pylori and
Helicobacter spp. in human liver samples from patients
suffering from primary sclerosing cholangitis and primary
biliary cirrhosis[17] and recently in liver samples of patients
with cholangiocarcinomas or HCC.
      Of great interest is the fact that the gene sequence obtained
from positive Helicobacter spp. specific 16S rRNA PCR was
usually most analogous to H pylori. This encourages the
speculation that the presence of Helicobacter DNA in human
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liver tissue might reflect the transport of H pylori of gastric
origin or its DNA to the liver. Studies have also indicated that
intestinal Helicobacter might be implicated in hepatobiliary
disease[17]. Recently, for the first time, the culture of a Helicobacter
strain from the human liver has been described. So far, few
studies have been reported regarding the presence of
Helicobacter spp. genomes in liver tissues from patients not
suffering from primary chronic liver diseases.
    We now report the infrequent presence of genomic
sequences of H pylori in liver parenchyma of patients operated
upon for metastasis to the liver arising from colon cancer. In
contrast, the presence of genome of Helicobacter spp. was
found with a higher frequency in the liver from patients with
HCV-related cirrhosis and HCC. This finding lends support to
the hypothesis that co-infection with H pylori or Helicobacter
spp. might amplify the chronic inflammation of the parenchyma,
thereby leading to cirrhosis and HCC[23]. To date, we do not
know whether bacterial infection of the liver could play a
pathogenic role in the development of human HCC, analogous
to what has been observed in the mouse model, and the question
awaits clarification.
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